Antony, Jane
Zanini, Elisa
Birtley, James R.
Gabra, Hani
Recchi, Chiara http://orcid.org/0000-0003-1605-0945
Article History
Received: 7 March 2020
Revised: 9 June 2020
Accepted: 10 June 2020
First Online: 29 June 2020
Compliance with ethical standards
:
: HG has ownership interest (including patents) to develop OPCML-based therapeutics. He is also Chief Medical Officer at BergenBio (producer of the AXL inhibitor BGB324). The remaining authors declare that they have no conflict of interest.